PUBLIC RELEASE DATE: 8-Oct-2014 Contact: Holly Ernest hernest@uwyo.edu 307-766-6605 University of California - Davis @ucdavis Cut off by freeways and human development, mountain lions in southern California are facing a severe loss of genetic diversity, according to a new study led by the University of California, Davis in partnership with The Nature Conservancy. The study, published today in the journal PLOS ONE, represents the largest genetic sampling of mountain lions, or pumas, in southern California. It raises concerns about the current status of mountain lions in the Santa Ana and Santa Monica mountains, as well as the longer-term outlook for mountain lions across southern California. UC Davis School of Veterinary Medicine scientists collected and analyzed DNA samples from 354 mountain lions statewide, including 97 from southern California. Pumas in the Santa Ana Mountains displayed lower genetic diversity than those from nearly every other region in the state. Santa Ana mountain lions show dramatic genetic isolation and have less in common with their neighbors in the Santa Monica Mountains than with those in the Sierra Nevada, underscoring the increasing seclusion of pumas in southern California. The Santa Ana Mountain range, located south of Los Angeles and north of San Diego, is … Continue reading →

Hamish Gilbert - Development of a Stem Cell Therapy forRepair of the Degenerate Intervertebral Disc Description. By: FMHSGraduateSociety … Continue reading →

Arthritis of shoulder; results four years after stem cell therapy by Harry Adelson, N.D. Heavy discusses his outcome four years out from his first bone marrow stem cell treatment for his arthritic shoulders and torn rotator cuffs by Harry Adelson, N.D. http://www.docereclinics.com. By: Harry Adelson, N.D. … Continue reading →

Michael Scott, a ViaCyte vice president, holds the VC-01 device that holds progenitor cells that will mature to make insulin and other hormones. More than ever before, stem cell therapies appear poised to transform medicine potentially curing heart disease, diabetes and paralyzing injuries, among other ailments. But its also clear that such innovations will be very expensive. How the government, insurers and patients will pay for what could be a flood of these new treatments drew the attention of more than 700 biomedical and health-care executives Tuesday at the 2014 Stem Cell Meeting on the Mesa. The annual conference, held on La Jolla's Torrey Pines Mesa, will run through Thursday. It brings together the business and academic worlds of cell therapy, including but not limited to stem cell treatments. In California alone, 131 clinical trials are taking place with stem cells, according to Clinicaltrials.gov, a government website that tracks clinical trials. Patients are being treated for conditions such as blindness from retinal diseases, HIV, leukemia, sickle cell disease, stroke and aging of skin. The recent proliferation of clinical trials marks great progress toward the ultimate goal of getting new treatments to patients, said stem cell researcher Jeanne Loring, who directs … Continue reading →

Willamette Valley, Oregon and Southwest Washington (PRWEB) October 09, 2014 Local veterinary surgeon Dr. Scott Gustafson is seeking candidates to participate in an investigational study of donor stem cells for dogs with osteoarthritis. Dr. Gustafson has lectured nationally on stem cell therapy and has performed clinical stem cell therapy for seven years. The ultimate goal of this study is to determine if a single injection of donor stem cells into one or two arthritically affected joints can help reduce pain and inflammation in the treated joints. Candidates for the current investigational study must be older than nine months, weigh more than five and a half pounds, have osteoarthritis of only one or two leg joints, have had pain or lameness for at least three months, and must not have cancer. Joints that will be included in the study and injected under anesthesia include hips, stifles, shoulders, and elbows. Dogs that may be considered must be in good health and undergo a diagnostic work up before qualifying for the study. Dr. Gustafson and his team coordinate directly with your veterinarian to provide the most advanced veterinary care available. Surgery 4 Pets mobile surgery provides the highest level of care and surgical … Continue reading →

#2 Cutting Edge of Science, Homeopathy Nanomedicine Part 2: A presentation at San Francisco's prestigious Commonwealth Club (September 17, 2014). The body of evidence for homeopathy and nanopharmacology is so much larger than most people ... By: Dana Ullman … Continue reading →

Laurent Levy, CEO of Nanobiotix said: "As planned, we should start the pivotal phase before the end of the year, the association of PharmaEngine to the trial is an excellent news. This reinforced collaboration will allow us to pool resources and data leading to a more impactful study for this first key indication. Moreover PharmaEngine's direct collaboration to the last phase of development of NBTXR3 is a new plan that should allow a faster access to the Asian market." Soft Tissue Sarcoma Following the very positive pilot Phase I results for advanced soft tissue sarcoma (STS) recently presented at the American Society of Clinical Oncology (ASCO) annual meeting, PharmaEngine and Nanobiotix have decided to accelerate the clinical development of NBTXR3 in the Asia-Pacific region. The planned European pivotal trial for NBTXR3 in soft tissue sarcoma will be broadened to Asia-Pacific where PharmaEngine will open additional clinical centers in multiple countries. Nanobiotix is sponsoring the global trial and PharmaEngine is co-sponsoring for the Asia-Pacific territory. The partners will bear the costs of the trial in their respective territories. The expanded soft tissue sarcoma trial will provide additional clinical centers in multiples countries in Asia-Pacific, a larger cohort of enrolled patients and … Continue reading →